Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on November 19, 2015, reporting on revisions to its 2014 Long-Term Incentive Plan award agreements. These revised agreements, approved by the Compensation Committee on November 13, 2015, will govern equity awards (stock options and restricted stock) granted to executive officers starting in December 2015. The changes are largely consistent with previous award agreements but include specific provisions for Dr. George D. Yancopoulos, President, Regeneron Laboratories and Chief Scientific Officer. Notably, Dr. Yancopoulos's revised award agreements introduce a 'Good Reason' termination clause related to a Change in Control. This provision allows Dr. Yancopoulos to terminate his employment and trigger accelerated vesting of his awards if the CEO, Dr. Leonard S. Schleifer, experiences an 'Involuntary Termination' within two years following a Change in Control. This signals a focus on executive retention and alignment with potential strategic events or leadership changes.
Key Highlights
- 1Regeneron updated its 2014 Long-Term Incentive Plan award agreements for executive officers, effective for 2015 annual equity awards.
- 2The revised agreements cover non-qualified stock options, incentive stock options, and restricted stock awards.
- 3The changes are generally consistent with prior award agreements.
- 4A key revision provides specific 'Good Reason' termination rights for Dr. George D. Yancopoulos upon a Change in Control under certain conditions.
- 5This provision is contingent on the CEO, Dr. Leonard S. Schleifer, having an 'Involuntary Termination' within two years post-Change in Control.
- 6The revised agreements aim to enhance executive retention and align incentives with potential future corporate events.